|
|
Review Article
Nebivolol might be Beneficial in Osteoporosis Treatment:
A Hypothesis
Aysun Toker1,
Erim Gulcan2, Serdar Toker3, Enver
Erbilen4, Elif Aksakalli5
1Department
of Biochemistry and Clinical Biochemistry, Yoncali
Physical Therapy and Hydrotheraphy Hospital, 2Department
of Internal Medicine, 3Department of
Orthopaedics and Traumatology, 4Department of
Cardiology, 5Department of Physical Therapy
and Rehabilitation, Dumlupinar University Faculty of
Medicine, Kutahya, Turkey.
E -mail:
drerimgulcan@gmail.com
Received:
20 September 2008
Revised accepted:
22 November 2008
Tropical
Journal of Pharmaceutical Research, April
2009; 8(2):
181-186
Abstract
Nebivolol
is a β-blocker that is highly selective for
β1-adrenergic receptors with vasodilating properties.
This property can be attributed to an endothelial
release of nitric oxide (NO). It has been reported that
nebivolol also reduces intracellular oxidative stress.
There are some studies conducted in humans and animal
models which have shown that NO is an important
regulator of bone metabolism. However, oxidative stress
and antioxidant systems may play important roles in the
pathogenesis of osteoporosis. In this paper, we
hypothesized that nebivolol may have beneficial effects
via nitric oxide and antioxidant action in osteoporosis
treatment.
Keywords:
Osteoporosis treatment, Nebivolol, Nitric oxide,
Anti-oxidant action
|
